SDC 1802
Alternative Names: SDC-1802Latest Information Update: 30 Jun 2025
At a glance
- Originator Sareum
- Class Antineoplastics; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor T-cell lymphoblastic leukaemia-lymphoma
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Jun 2025 SDC 1802 is still in preclinical trials for Precursor-T-cell-lymphoblastic-leukaemia-lymphoma in United Kingdom
- 28 Jan 2025 No recent reports of development identified for preclinical development in Precursor-T-cell-lymphoblastic-leukaemia-lymphoma in United Kingdom (PO)
- 28 Jul 2024 No recent reports of development identified for preclinical development in Systemic-lupus-erythematosus in United Kingdom (PO)